Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology

Carcinogenesis

Volumn 31, Issue 3, 2010, Pages 512-520

  Lim, Soyoung ^a   Janzer, Andreas ^a   Becker, Astrid ^a   Zimmer, Andreas ^a   Schüle, Roland ^b   Buettner, Reinhard ^a   Kirfel, Jutta ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN A2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HISTONE H3; LYSINE SPECIFIC DEMETHYLASE 1; METHYL GROUP; PROTEIN P21; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AOF2 PROTEIN, HUMAN; CCNA2 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE; HISTONE DEMETHYLASE; PROGESTERONE RECEPTOR; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGENETICS; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA INTERFERENCE; ADENOCARCINOMA; BIOSYNTHESIS; BREAST TUMOR; CANCER INVASION; CHEMISTRY; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; GENETICS; METHYLATION; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROTO ONCOGENE; TUMOR CELL LINE;

ADENOCARCINOMA; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CYCLIN A2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENES, ERBB-2; HISTONE DEMETHYLASES; HISTONES; HUMANS; METHYLATION; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 77950868547     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp324     Document Type: Article

References (46)

1. Fraga, M.F. et al. (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet., 37, 391-400.
2. Mann, B.S. et al. (2007) Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin. Cancer Res., 13, 2318-2322.
3. Jenuwein, T. et al. (2001) Translating the histone code. Science, 293, 1074-1080.
4. Lachner, M. et al. (2003) An epigenetic road map for histone lysine methylation. J. Cell Sci., 116, 2117-2124.
5. Klose, R.J. et al. (2006) The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature, 442, 312-316.
6. Metzger, E. et al. (2005) LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature, 437, 436-439.
7. Shi, Y. et al. (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell, 119, 941-953.
8. Tsukada, Y. et al. (2006) Histone demethylation by a family of JmjC domain-containing proteins. Nature, 439, 811-816.
9. Whetstine, J.R. et al. (2006) Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell, 125, 467-481.
10. Wissmann, M. et al. (2007) Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat. Cell Biol., 9, 347-353.
11. Yamane, K. et al. (2006) JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell, 125, 483-495.
12. Garcia-Bassets, I. et al. (2007) Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell, 128, 505-518.
13. Shi, Y.J. et al. (2005) Regulation of LSD1 histone demethylase activity by its associated factors. Mol. Cell, 19, 857-864.
14. Wang, J. et al. (2007) Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature, 446, 882-887.
15. Schulte, J.H. et al. (2009) Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res., 69, 2065-2071.
16. Kahl, P. et al. (2006) Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res., 66, 11341-11347.
17. Remmele, W. et al. (1986) Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows. Arch. A. Pathol. Anat. Histopathol., 409, 127-147.
18. Goidin, D. et al. (2001) Ribosomal 18S RNA prevails over glyceraldehyde-3-phosphate dehydrogenase and beta-actin genes as internal standard for quantitative comparison of mRNA levels in invasive and noninvasive human melanoma cell subpopulations. Anal. Biochem., 295, 17-21.
19. Cui, X. et al. (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J. Clin. Oncol., 23, 7721-7735.
20. Lee, M.G. et al. (2006) Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem. Biol., 13, 563-567.
21. Scoumanne, A. et al. (2007) The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners. J. Biol. Chem., 282, 15471-15475.
22. Osthus, R.C. et al. (2005) The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo. Cancer Res., 65, 5620-5627.
23. McIntyre, E. et al. (2009) The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer. Breast Cancer Res. Treat., [Epud ahead of print].
24. Strebhardt, K. et al. (2006) Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer, 6, 321-330.
25. Traub, F. et al. (2006) Prognostic impact of Skp2 and p27 in human breast cancer. Breast Cancer Res. Treat., 99, 185-191.
26. O'Brien, S.L. et al. (2007) CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int. J. Cancer, 120, 1434-1443.
27. Santisteban, M. et al. (2009) Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Res. Treat., [Epud ahead of print].
28. Worku, D. et al. (2008) Evidence of a tumour suppressive function of E2F1 gene in human breast cancer. Anticancer Res., 28, 2135-2139.
29. Ramachandran, C. et al. (2005) Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines. Anticancer Res., 25, 3293-3302.
30. Husdal, A. et al. (2006) The prognostic value and overexpression of cyclin A is correlated with gene amplification of both cyclin A and cyclin E in breast cancer patient. Cell Oncol., 28, 107-116.
31. Harper, J.W. et al. (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805-816.
32. Marchio, C. et al. (2008) The genomic profile of HER2-amplified breast cancers: the influence of ER status. J. Pathol., 216, 399-407.
33. Forneris, F. et al. (2008) LSD1: oxidative chemistry for multifaceted functions in chromatin regulation. Trends Biochem. Sci., 33, 181-189.
34. Bradley, C. et al. (2007) Carcinogen-induced histone alteration in normal human mammary epithelial cells. Carcinogenesis, 28, 2184-2192.
35. Esteller, M. (2008) Epigenetics in cancer. N. Engl. J. Med., 358, 1148- 1159.
36. Ding, L. et al. (2006) Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast. Cancer Res., 66, 9352-9355.
37. Gartenhaus, R.B. et al. (1996) Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytesafter treatment with adriamycin by using a p53-independent pathway. Proc. Natl Acad. Sci. USA, 93, 265-268.
38. Abbas, T. et al. (2009) p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer, 9, 400-414.
39. Fraczek, M. et al. (2008) Clinicopathologic significance and prognostic role of cyclin E and cyclin A expression in laryngeal epithelial lesions. Acta Otolaryngol., 128, 329-334.
40. Patel, R.S. et al. (2007) Cyclin A expression and its diagnostic value in pleomorphic adenoma and carcinoma expleomorphic adenoma of the parotid gland. Histopathology, 51, 21-25.
41. Sunami, E. et al. (2008) Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res., 10, R46.
42. Chen, Q. et al. (2004) Distinct capacities of individual E2Fs to induce cell cycle reentry in postmitotic lens fiber cells of transgenic mice. Dev. Neurosci., 26, 435-445.
43. Pellikainen, J.M. et al. (2007) Activator protein-2 in carcinogenesis with a special reference to breast cancer-a mini review. Int. J. Cancer, 120, 2061-2067.
44. Huang, Y. et al. (2007) Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc. Natl Acad. Sci. USA, 104, 8023-8028.
45. Wang, J. et al. (2009) The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet., 41, 125-129.
46. Lo, P.K. et al. (2008) Epigenomics and breast cancer. Pharmacogenomics, 9, 1879-1902